- Trial Phase
- Approved (NMPA)
- Time to Market
- Already approved in China (NMPA approval granted August 4, 2026). Commercial launch timeline in China is unknown but the drug is now market-authorized.
- Why 2/10
- PVRV-SF is already NMPA-approved (Aug 4, 2026) with no upcoming binary catalyst. Sinovac's stock (SVA) has been halted on Nasdaq since Feb 2019 with no trading activity, so any drug-related news cannot drive a share-price move. ImpactScore is 2: the drug is approved but the stock is untradeable.
PVRV-SF's NMPA approval is a positive pipeline event but irrelevant for investors because SVA stock has been halted since Feb 2019 with no active trading. The company's severe financial losses, governance crisis, and Nasdaq limbo make this a 'show-me' story with no tradable catalyst. Do not invest in SVA until trading resumes and the governance/audit issues are resolved.
Price Chart
Executive Summary
PVRV-SF is Sinovac Biotech's purified Vero cell rabies vaccine that received NMPA marketing approval in China on August 4, 2026. While this is a positive pipeline milestone adding a new commercial vaccine to Sinovac's portfolio, the company's stock (SVA) has been halted on Nasdaq since February 2019 with no active trading market. Sinovac faces severe financial distress (widening losses, cash burn, drained retained earnings), a governance crisis (contested board, no shareholder meetings since 2018), and regulatory limbo (Nasdaq Mandatory Panel Monitor through May 2027). The NMPA approval does not address these fundamental issues, and the stock remains untradeable for investors.
How It Works
PVRV-SF is a purified rabies vaccine grown on Vero cells (a standard kidney-cell line from African green monkeys used to manufacture viral vaccines). It works by exposing the immune system to inactivated rabies virus, training the body to produce antibodies that neutralize the rabies virus if the vaccinated person is later bitten by a rabid animal. It is given after exposure (post-exposure prophylaxis) to prevent the fatal disease.
Trial Status
PVRV-SF received NMPA (China's National Medical Products Administration) marketing approval on August 4, 2026, as disclosed in Sinovac's H1 2026 6-K filing with the SEC on August 17, 2026. The drug is now approved for commercial sale in China as a rabies post-exposure prophylaxis vaccine.
The Two-Sided Case
Upcoming Catalysts
- No upcoming binary catalyst for PVRV-SF — it is already NMPA-approved. The stock (SVA) remains halted on Nasdaq since Feb 2019 with no trading activity.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
SINOVAC BIOTECH LTD 6-K SVA ·Originating report